Recruiting
Vitiligo
RecruitingInvestigational
Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo
Investigational
- Disease:Vitiligo
- Substances:–
Countries:
France
France- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 8
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
1 503 trials match your criteria
Recruiting
Endometrial cancer+8
RecruitingInvestigationalNo placebo
Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors
InvestigationalNo placebo
- Disease:Endometrial cancerGastric cancer+7
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
Recruiting
Myelofibrosis+1
RecruitingRegistered drug
Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive
Registered drug
- Disease:MyelofibrosisPrimary myelofibrosis
- Substances:Ruxolitinib2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Ruxolitinib
Recruiting
Rheumatoid arthritis
RecruitingInvestigational
Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study
Investigational
- Disease:Rheumatoid arthritis
- Substances:Ro7790121
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Ro7790121
Recruiting
InvestigationalNo placebo
Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
InvestigationalNo placebo
- Disease:Dementia of the Alzheimer's type with delusions
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Recruiting
Plasma cell myeloma refractory
RecruitingInvestigationalNo placebo
Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
InvestigationalNo placebo
- Disease:Plasma cell myeloma refractory
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
Recruiting
Non-small cell lung cancer stage III
RecruitingRegistered drugNo placebo
Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
Registered drugNo placebo
- Disease:Non-small cell lung cancer stage III
- Substances:Durvalumab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Durvalumab
Recruiting
Chronic spontaneous urticaria
RecruitingInvestigationalNo placebo
Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial
InvestigationalNo placebo
- Disease:Chronic spontaneous urticaria
- Substances:Remibrutinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Hormone-dependent prostate cancer
RecruitingRegistered drugNo placebo
Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment
Registered drugNo placebo
- Disease:Hormone-dependent prostate cancer
- Substances:ApalutamideDocetaxel
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Apalutamide
Recruiting
Colorectal cancer metastatic
RecruitingRegistered drug
INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Registered drug
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+2
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Systemic lupus erythematosus
RecruitingInvestigational
Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Investigational
- Disease:Systemic lupus erythematosus
- Substances:Nipocalimab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Nipocalimab
Recruiting
Plasma cell myeloma refractory
RecruitingInvestigationalNo placebo
JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
InvestigationalNo placebo
- Disease:Plasma cell myeloma refractory
- Substances:TeclistamabIGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Teclistamab